drugset / Trial / NCT00684944
Open Label Study of TRx0014 in Alzheimer's Disease
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open label, dose-ranging study of two doses of TRx0014 in patients with mild or moderate Alzheimer's Disease. The trial is made available to any patient ongoing on treatment in the clinical trial designated TRx-014-001 at termination of that study. Treatment for each individual patient will continue for as long as the treating physician feels there is benefit to the patient. This current protocol covers each patient for 12 months in the first instance.
Timeline
- Start
- 2007-09-13
- Primary completion
- 2010-12-02
- Completion
- 2010-12-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Methylene Blue | Diagnostic / imaging agent | 30 mg | — |
| Comparator | Methylene Blue | Diagnostic / imaging agent | 60 mg | — |